



Neogap receives Notice of Allowance for European patent

Neogap Therapeutics AB announces today that the European Patent Office issued a Notice of Allowance covering ex vivo tumour selective T-cell expansion using EpiTCer technology and compositions of cells prepared using the method.

The Notice of Allowance means that the European Patent Office intends to grant the patent application, EP18735229.9, after the completion of certain formal steps. Once granted, the patent can be kept in force until 2038.

“We are very pleased that we have got a Notice of Allowance in Europe for this patent application which adds increased value to our immune-oncology pipeline and strengthens NEOGAP's patent portfolio. We will continue to develop our portfolio of proprietary assets to support our unique cancer therapies further”, says Samuel Svensson, CEO of Neogap.

For more information, please contact:

Samuel Svensson, CEO
Phone: +46 733 54 21 94
Email: samuel.svensson@neogap.se

About Neogap Therapeutics

NEOGAP Therapeutics is a Swedish biotechnology company that develops individualised immunotherapy for the treatment of cancer using the patient's own cells. The therapy is based on the company's two technologies: PIOR®, a software using DNA sequencing data from the patient and machine learning to select tumour-specific mutations; and EpiTCer®, a method for proliferating the T cells that recognize the selected tumour-specific target structures. NEOGAP is located at the Center for Molecular Medicine, Karolinska Institutet in Stockholm. For more information, visit the company's website neogap.se.